Introduction
There are currently two classes of antiviral drugs that are globally approved for the treatment of influenza in humans, the adamantanes (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir). Wide-spread use of these antiviral agents as monotherapy has contributed to the emergence of influenza viruses that are resistant to compounds from both drug classes (de Jong et al., 2005; Ison et al., 2006b; Ison et al., 2006a; Li et al., 2015) . Indeed, the frequency of adamantane resistance in circulating influenza strains is so high that amantadine is no longer recommended for the treatment of influenza (Hayden, 2006) . Oseltamivir-resistant influenza has also been detected, but the prevalence of these strains is seasonal. This was demonstrated during the 2008-2009 influenza season where nearly 100% of all H1N1 isolates were resistant to oseltamivir in the United States and Japan (CDC, 2009a; Matsuzaki et al., 2010) . This oseltamivir-resistant seasonal virus was displaced by the spread of 2009 H1N1 pandemic influenza, which was susceptible to oseltamivir and became the predominant strain. Influenza viruses currently in circulation are sensitive to oseltamivir with only a few sporadic cases of resistance reported (CDC, 2009c; CDC, 2009b) . Finally, zanamivir-resistant viruses have been described, albeit very infrequently (Hurt et al., 2009) . The low prevalence of zanamivir-resistance is likely tied to the low clinical use of this agent due to poor oral bioavailability; consequently, zanamivir is administered via inhalation with a disk-inhaler (GlaxoSmithKline, 2009 ). This method of delivery is not suitable for patient populations that have the highest morbidity and mortality rates from influenza, including children, those with underlying respiratory ailments (i.e.: asthma or chronic obstructive pulmonary disease), or the severely ill. An intravenous (i.v.) formulation of zanamivir is available, but is not currently approved by the Food and Drug Administration despite demonstrating good efficacy in critically-ill hospitalized influenza patients (Dulek et al., 2010; Marty et al., 2014; Watanabe et al., 2015) .
The emergence and spread of drug-resistant influenza is a significant public health concern and transmission of such viruses may ultimately render antiviral intervention useless. Combination therapy with two or more agents has potential to enhance effectiveness and counter drug-resistance, as demonstrated by the success of multiple drug regimens for the treatment of hepatitis C virus and human immunodeficiency virus (Foster et al., 2015; Gane et al., 2013; Zeuzem et al., 2013; Autran et al., 1997; Larder et al., 1995; Markowitz et al., 2007; Markowitz et al., 2009 ). However, this therapeutic approach has only been occasionally investigated for influenza. One glaring obstacle for combination therapy is the lack of approved compounds with different mechanisms of action. Presently, only the neuraminidase inhibitors (oseltamivir and zanamivir) are prescribed for influenza. Combination therapy with oseltamivir and zanamivir is reasonable because these agents bind within the neuraminidase active site differently (Moscona, 2005) . In order for oseltamivir to bind into the active site, a conformational change must occur within the neuraminidase to accommodate the steric bulk of the drug whereas zanamivir binds directly to the neuraminidase without any structural rearrangement (Moscona, 2005) . These mechanistic differences in binding explain why oseltamivir and zanamivir have non-overlapping resistance profiles, so that oseltamivir-resistant influenza viruses remain susceptible to zanamivir and vice versa. Additionally, the likelihood of selecting for viruses that are dually resistant to both oseltamivir and zanamivir is low. Thus, combination therapy with these two agents may serve as a rational strategy to overcome the emergence of resistance. Peramivir was not evaluated in these studies since oseltamivir and peramivir have overlapping resistance profiles (Takashita et al., 2014) .
The main objective of this study was to evaluate the effectiveness of oseltamivir and zanamivir as combination therapy against influenza A viruses and, more importantly, assess the ability of this regimen to prevent the emergence and spread of resistance. This therapeutic strategy of using two drugs with the same mechanism of action to combat influenza resistance is novel and may serve as a strategy to fight other viral and non-viral infections for which multiple classes of antiinfective drugs do not exist. (Brown et al., 2010) . MDCK cells (ATCC #CCL-34) were purchased from the American Type Culture Collection (Manassas, VA) and maintained in minimal essential medium (MEM; Hyclone, Logan, UT) [supplemented with 10% fetal bovine serum (FBS), non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/mL of penicillin, 100 μg/mL of streptomycin, and 1.5 g/L sodium bicarbonate] at 37°C and 5% CO 2 .
Materials and methods

Viruses and cells
Compounds
Oseltamivir carboxylate was obtained from Hoffmann-La Roche Inc. (Nutley, NJ) and zanamivir was provided by GlaxoSmithKline (Philadelphia, PA). Both drugs were reconstituted in sterile distilled water to a final active concentration of 10 mg/mL, filter-sterilized through a 0.2 μm filter, and aliquoted. Oseltamivir aliquots were stored at 4°C and zanamivir aliquots were stored at −80°C. Fresh drug stocks were prepared at the beginning of each study.
Drug susceptibility assay
The antiviral activity of oseltamivir and zanamivir against influenza was determined using the commercially available chemiluminescencebased NA-Star influenza neuraminidase inhibitor resistance detection kit (Applied Biosystems, Foster City, CA), as per the manufacturer's instructions. The 50% inhibitory concentration (IC 50 ) values were calculated using GraphPad Prism software (GraphPad, La Jolla, CA).
The hollow fiber infection model (HFIM) system
The hollow fiber infection model (HFIM) system has been described previously (Brown et al., 2010; Brown et al., 2011a; McSharry et al., 2009 Five different oseltamivir and/or zanamivir dosage regimens were evaluated against each virus inoculation condition. The 24-h area under the concentration-time curve (AUC) for exposures associated with oral oseltamivir at 75 mg twice daily (Q12) and i.v. zanamivir at 600 mg Q12 were delivered into HF cartridges, either alone (monotherapy) or in combination, as a 1 h infusion via computer-programed syringe pumps. The pharmacokinetic (PK) profiles for oseltamivir and zanamivir in HF units were extrapolated from average human serum PK data (Doucette and Aoki, 2001; GlaxoSmithKline, 2009) . The reported human half-lives of 8 h for oseltamivir (Doucette and Aoki, 2001 ) and 2.5 h for zanamivir (GlaxoSmithKline, 2009) were simulated in these experiments. One cartridge for each virus inoculum did not receive drug treatment and served as a no-treatment control. Finally, two additional experimental arms were included in which oseltamivir and zanamivir were administered as monotherapy at an exposure equivalent to the oseltamivir-zanamivir combination arm to ensure that any additional effect from the combination was not solely due to the higher drug exposure in this arm. These two arms are termed "monotherapy high exposure". The simulated PK profiles for oseltamivir and zanamivir in the HFIM system are depicted in Fig. 1 .
The ECS from each HF cartridge was sampled every 24 h. Samples were harvested from the left and right sampling ports, centrifuged for 5 min at 10,000 x g to remove cell debris, and frozen at −80°C until the end of the study. Viral burden was assessed by plaque assay on MDCK cells as previously described (Brown et al., 2011a; Hayden et al., 1980) . HF experiments with MX/09, HK/09-H275Y, and 99% MK/ 09 + 1% HK/09-H275Y were conducted simultaneously. Experiments with BZ/08-Q136K were performed independently.
Pyrosequencing
Pyrosequencing was performed to quantify HK/09-H275Y populations in HF arms inoculated with a mixed virus infection, as previously described (Deyde et al., 2010) . Briefly, template preparation of biotinylated PCR products for pyrosequencing was performed according to the manufacturer's protocol using the Vacuum Prep Workstation (Biotage AB, Uppsala, Sweden) and Streptavidin Sepharose HP (Amersham Biosciences), with the following modifications: 1) the final concentration of sequencing primer used in the annealing step was 0.5 μM; and 2) the primer annealing step was done by placing the plate on a heat block set to 85°C for 2 min, followed by cooling on the bench for 5 min (on the thermoplate), and then removing the plate from the thermoplate and cooling for an additional 5 min directly on the benchtop. Pyrosequencing of samples were done by the Wadsworth Center Applied Genomic Technologies Core Facility, using a PyroMark ID pyrosequencer (Biotage AB, Uppsala, Sweden) following the manufacturer's protocol. Samples were sequenced in SNP mode (analysis version 1.0.5) with the directed dispensation: GATCGACTA. Sequences were analyzed in Allele-Quantification (AQ) mode, which calculates the percentage of each allele in the sequence of interest. Each result is given a quality value of Pass, Check, or Failed. Quality assessment criteria include warnings for low signal-to-noise ratio, wide peaks and possible dispensation errors for results that do not receive a value of pass.
Oseltamivir and zanamivir concentrations in the HFIM system
The concentration of oseltamivir and/or zanamivir was quantified in each sample by high-pressure liquid chromatography-tandem mass spectrometry (HPLC-MS-MS). The LC-MS-MS methods for oseltamivir (McSharry et al., 2009 ) and zanamivir (Brown et al., 2011a) are published elsewhere. Oseltamivir and zanamivir concentrations in the HFIM system were within 10% of the desired value at all time points in all experimental arms (data not shown).
Results
Susceptibilities of influenza strains to oseltamivir and zanamivir
The antiviral activities of oseltamivir and zanamivir against wildtype and mutant influenza A viruses were evaluated using the chemiluminescent NA-STAR assay (Table 1) . As expected, HK/09-H275Y was resistant to oseltamivir, with an IC 50 of 15.30 ng/mL, but sensitive to zanamivir (IC 50 = 0.0024 ng/mL). Conversely, BZ/08-Q136K was resistant to zanamivir (IC 50 = 5.779 ng/mL) but retained sensitivity to oseltamivir (IC 50 = 0.0028 ng/mL). MX/09 had IC 50 values similar to those reported for other H1N1 wild-type influenza viruses (Brown et al., 2011b; Richard et al., 2011; Sheu et al., 2008) , demonstrating that it is sensitive to both neuraminidase inhibitors (Table 1) .
HFIM studies with oseltamivir and zanamivir against 2009 pandemic H1N1 influenza
The antiviral activity of oseltamivir and/or zanamivir was evaluated against MX/09 and HK/09-H275Y as single or mixed virus infections (99% MX/09 + 1% HK/09-H275Y) in the HFIM system. MX/09 and HK/09-H275Y exhibited robust replication in the HFIM system with similar kinetics in the absence of drug ( Fig. 2A-B) . Moreover, peak viral titers in the no-treatment control arms were slightly higher (approximately 0.6-log 10 ) with HK/09-H275Y compared to MX/09, indicating that the H275Y mutation does not have a negative impact on viral fitness. Replication kinetics between the no-treatment control arms for the mixed viral infection and MX/09 were nearly identical ( Fig. 2A, C) and demonstrate that HK/09-H275Y does not preferentially replicate over MX/09 in combination.
Oseltamivir and zanamivir, whether alone or in combination, suppressed the replication of MX/09 throughout the study relative to the no-treatment control (Fig. 2A) ; however, greater inhibition was observed in the experimental arms that contained higher exposures of drug (Oseltamivir monotherapy high exposure, zanamivir monotherapy high exposure, and oseltamivir/zanamivir combination therapy) relative to standard clinical regimens. Although oseltamivir monotherapy delayed viral replication and blunted peak viral titers, treatment failed to completely suppress HK/09-H275Y, even in the presence of higher drug exposures. Zanamivir monotherapy, regardless of exposure, was effective against HK/09-H275Y, providing sustained viral suppression and reducing peak viral titers by approximately 4-log 10 PFU/mL (Fig. 2B) . Combination therapy displayed substantial antiviral activity against HK/09-H275Y and was as effective as zanamivir monotherapy (Fig. 2B) .
For the mixed virus infection, viral burden was suppressed in all treatment arms relative to the no-treatment control at 24 h post-treatment (Fig. 2C) . After 24 h, viral titers rapidly increased in the oseltamivir monotherapy regimen, achieving a peak viral load equivalent to that of the no-treatment control by 72 h. The oseltamivir monotherapy high exposure treatment arm provided some suppression over the standard clinical regimen at 24 h; however, viral burden in this arm was similar to that of the no-treatment control at 48 h and beyond. 
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Zanamivir at the clinical exposure and high exposure provided similar levels of sustained viral inhibition, as viral burden was at least 2-log 10 lower than the no-treatment control throughout the experiment. Combination therapy with oseltamivir and zanamivir was as effective as zanamivir treatment arms and inhibited viral burden with nearly identical kinetics (Fig. 2C) . MK/09 and HK/09-H275Y subpopulations were quantified in samples harvested from HF cartridges inoculated with the mixed viral infection by pyrosequencing. As expected, MX/09 was dominant in the no-treatment control arm and comprised at least 97% of the total population at all time-points (Fig. 3A) . Oseltamivir monotherapy at the standard clinical exposure rapidly selected for HK/09-H275Y, which became the dominant viral strain by 48 h post-therapy (Fig. 3B) . By 96 h post-treatment, the mixed viral infection contained only HK/09-H275Y. Oseltamivir monotherapy at the high exposure delayed the selection of HK/09-H275Y; but, this level of exposure was unable to completely suppress viral replication over time, as HK/09-H275Y subpopulations increased to 76% by 96 h post-treatment and 83% by 120 h (Fig. 3C) . In contrast, all zanamivir-containing regimens (the clinical monotherapy exposure, high monotherapy exposure, and oseltamivir/ zanamivir combination regimen) prevented the replication of HK/09-H275Y throughout the duration of the study, maintaining levels of HK/ 09-H275Y that were comparable to the no-treatment control (Fig. 3D-F) .
Oseltamivir and/or zanamivir treatment against influenza that is resistant to zanamivir
Oseltamivir and/or zanamivir regimens were also evaluated against BZ/08-Q136K to determine if combination therapy is effective at suppressing viruses that are resistant to zanamivir. In this case, zanamivir monotherapy at both exposure levels was unable to inhibit BZ/ 08-Q136K replication; however, treatment did delay replication kinetics and reduce peak viral titers (Fig. 4) . Oseltamivir monotherapy was effective against BZ/08-Q136K, as viral titers in these arms were markedly lower than those reported for the no-treatment control and zanamivir monotherapy regimens (Fig. 4) . Greater viral suppression was observed in the oseltamivir monotherapy high exposure arm compared to the standard clinical oseltamivir regimen. Oseltamivir/ zanamivir combination therapy was also effective against BZ/08-Q136K and achieved a degree of viral inhibition that was comparable to the oseltamivir monotherapy high exposure regimen (Fig. 4) .
Discussion
The emergence and spread of drug-resistant influenza viruses will compromise the effectiveness of our already limited influenza-therapeutic armamentarium. This danger was observed during the 2009 influenza A H1N1 pandemic, in which viruses resistant to amantadine, rimantidine, and oseltamivir were reported (CDC, 2009d; CDC, 2009c; CDC, 2009b; CDC, 2009a) . These surveillance data provide evidence that current prophylactic and/or treatment regimens with influenza antivirals can occasionally select for the emergence and possible spread of resistance.
Previous reports have documented the presence of oseltamivir-resistant subpopulations at low levels in influenza infected individuals that have not received oseltamivir therapy (Ghedin et al., 2012) . These findings have important implications for anti-influenza therapy, as we have demonstrated here that the current clinical regimen of oseltamivir (75 mg twice-daily) rapidly selects for oseltamivir-resistant subpopulations in a mixed viral infection that contains 1% of resistant virus at the start of treatment (Fig. 1C) . Furthermore, we showed that oseltamivir monotherapy at an exposure that is 8-times higher than the clinical dose is also unable to inhibit drug-resistant viruses (Fig. 1C) . It is important to note that our studies were conducted in an in vitro setting that is devoid of an immune system. If a functioning immune component was present, resistance would likely have been better contained. Our model more accurately represents influenza infections in immunocompromised individuals, a patient population in which resistant influenza is more prevalent. Nevertheless, these results highlight the shortcomings of the available influenza treatment regimens. In the absence of new antiviral agents for influenza, innovative therapeutic regimens with licensed compounds are needed to aid in the prevention of resistance. The objective of this study was to evaluate combination therapy with two available neuraminidase inhibitors as a means to suppress drug-resistant viruses.
Although oseltamivir and zanamivir target the same viral protein (the neuraminidase), they bind to the active site differently. Oseltamivir activity requires that the neuraminidase change shape to create a pocket that will accommodate the steric bulk of the drug. In contrast, zanamivir can bind directly into the active site without a conformational change (Moscona, 2005) . These mechanistic differences illustrate that oseltamivir and zanamivir bind to distinct residues within the active site of the neuraminidase. However, since only one agent can occupy the active site at a time, the likelihood of obtaining increased viral suppression with the combination is low. The benefit to these binding differences is that the resistance profiles between oseltamivir and zanamivir do not overlap so that these agents may be used effectively to prevent resistance to either drug when used in combination. Our results substantiated both of these scenarios, as combination therapy was as effective as the most active monotherapy treatment and showed considerable activity against oseltamivir-and zanamivir-resistant viruses. Moreover, oseltamivir/zanamivir combination therapy was able to suppress the selection of oseltamivir-resistant viruses in a mixed infection model.
Due to its effectiveness against resistant viruses, combination therapy is likely to be more beneficial to standard monotherapy regimens, particularly during an influenza pandemic when a vaccine is not yet available and in a population of individuals who are at high risk for morbidity and mortality (i.e.: nursing homes, hospitalized patients, and immunocompromised individuals). Implementing this strategy could also preserve the clinical utility of neuraminidase inhibitors by preventing the spread of drug-resistant strains.
The feasibility of oseltamivir-zanamivir combination therapy has C.P. Pires de Mello et al. European Journal of Pharmaceutical Sciences 111 (2018) 443-449 been evaluated in clinical trials with varying conclusions related to therapeutic outcomes. Carrat et al. (Carrat et al., 2012) demonstrated that combination therapy with oseltamivir and zanamivir was more effective than monotherapy at reducing influenza household transmission when administered to the index patient within 24 h of symptom onset. This study analyzed a subset of patients that was part of a larger randomized placebo-controlled trial conducted by Duval et al. (Duval et al., 2010) . Combination therapy in the Duval et al. study was less efficacious than oseltamivir monotherapy, but displayed similar levels of effectiveness compared to zanamivir monotherapy in patients infected with H3N2 influenza (Duval et al., 2010) . These findings contrast with our results, as antiviral effectiveness was not compromised in the face of combination therapy in the HFIM system. The disparity in conclusions may be attributed several factors including differences in the route of administration for zanamivir, as we simulated profiles associated with i.v. administration whereas Duval et al. administered via inhalation with a rotadisk inhaler. The inhaler is difficult to operate and misuse can result in suboptimal drug concentrations at the infection site (Diggory et al., 2001) , which may explain the lack of effectiveness in patients treated with zanamivir. Finally, the authors did stipulate that the results in the combination treatment arm may have been underestimated due to missing data points. A subset analysis was performed including only patients with available virological data and showed nonsignificant differences in effectiveness between combination therapy compared to oseltamivir monotherapy (p = 0.06), although patients treated with oseltamivir alone experienced a greater reduction in viral burden (~0.35-log 10 cgeq/μL) than those treated with the combination (Duval et al., 2010) . Viruses resistant to oseltamivir or zanamivir were not detected in this study. A small clinical study (21 patients) reported that oral oseltamivir and inhaled zanamivir combination therapy failed to reduce influenza replication in patients with severe influenza pneumonia (Petersen et al., 2011) . Monotherapy arms were not conducted as part of this evaluation, so therapeutic outcomes were not compared between combination and single agent regimens. The patients in this evaluation were critically ill, with nine patients requiring extracorporeal membrane oxygenation (ECMO). Furthermore, combination therapy was initiated late in infection, which likely played a major role in lack of efficacy because neuraminidase inhibitors are most beneficial when administered within 48 h of symptom onset. Oseltamivir-resistance was detected in one patient, but the patient ultimately cleared the resistant isolate.
Escuret et al. conducted another small clinical trial (24 patients) in which the effectiveness of oseltamivir/zanamivir combination therapy was compared to oseltamivir monotherapy in patients with 2009 pandemic H1N1 influenza infections (Escuret et al., 2012) . No significant differences in viral burden or clinical outcome were detected between treatment arms. Additionally, oseltamivir-resistant mutants were not detected in any patient at day 2 or 3 post-treatment in nasal wash samples using an assay with a limit of sensitivity of 10%. Resistance profiles at baseline were not conducted.
The value of oseltamivir/zanamivir combination therapy in regards to resistance suppression has yet to be defined. Studies conducted in mice have attempted to address this issue. Pizzorno et al. showed that the effectiveness of oseltamivir/zanamivir combination therapy was comparable to zanamivir monotherapy and significantly better than oseltamivir monotherapy in mice infected with oseltamivir-resistant H1N1 2009 pandemic influenza (Pizzorno et al., 2014) . The findings from this study illustrate that oseltamivir is ineffective against an oseltamivir-resistant isolate, but that zanamivir is active against oseltamivir-resistant viruses in vivo whether alone or in combination. Our experiments build upon this study, as we evaluated the combination regimen against many different drug-resistant infection scenarios including, oseltamivir-resistant influenza, zanamivir-resistant influenza, and a mixed virus infection that contained low levels of oseltamivirresistant influenza. Moreover, in our system we are able to simulate human pharmacokinetic profiles for both oseltamivir and zanamivir; this was not accomplished in the mouse model.
Conclusions
In summary, we have shown that combination therapy with oseltamivir and zanamivir is an effective therapeutic strategy for preventing resistance with seasonal and pandemic influenza. We acknowledge that combination therapy with agents from different drug classes would be ideal, as enhanced antiviral activity as well as resistance suppression should occur with these regimens. Currently only neuraminidase inhibitors are approved for the treatment of influenza; but, new compounds (i.e.: favipiravir and pimodivir) with novel mechanisms of action are in clinical trials. We will evaluate combination therapy with these new agents as they become available. Until then, our results demonstrate the potential utility of combining two agents with the same mechanism of action but distinct binding profiles to the target protein to combat drug-resistance during antiviral therapy. This finding is novel for influenza and significant, considering that the emergence of resistance is a major challenge for this disease. These strategies should be tested for other viral and non-viral diseases for which multiple classes of anti-infective agents do not yet exist.
